Effect of Cinnora in treatment of idiopathic granulomatous mastitis resistance to Prednisolone

Phase 3

Recruiting

• Conditions: Idiopathic granulomatous mastitis.; Granulomatous disorder of the skin and subcutaneous tissue, unspecified; L92.9

• Registration Number: IRCT20211018052807N1
• Lead Sponsor: Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients with granulomatous mastitis in breast mass pathology in whom the known causes of granulomatous mastitis have been ruled out
Resistance to prednisolone treatment with a dose of 20 to 30 for 3 months
Hepatitis B, hepatitis C and TB negative

Exclusion Criteria

Patients with infectious mastitis or positive bacterial culture
Patients with granulomatous mastitis with caseous necrosis
Patients with culture or PCR positive for TB
People with breast cancer
Patients with hepatitis B or hepatitis C positive

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response to treatment. Timepoint: monthly. Method of measurement: Lack of response is considered if the clinical and paraclinical symptoms improve by less than 25% , in case of improvement 25 to 75% relative response and in case of improvement above 75%, the answer is considered complete.